Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 10/16 04:00:46 pm
17.23 EUR   -1.49%
09/06 PCAS : Résultats au 1er semestre 2017
09/05 NOMBRE TOTAL DE : Août 2017
09/01PCAS SA : half-yearly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

PCAS : Quarterly Financial Information as of March 31st 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 05:40pm CEST

PCAS: Quarterly Financial Information As of March 31st, 2012

 
 
 
 

Longjumeau, April 23rd,  2012

Business update

(in million of euros) 2012 2011 % change
Sales as of 31 March 42 728 44 053 -3,0%
including Pharmaceutical Synthesis 25 454 27 147 -6,2%
including Specialty Chemicals 17 274 16 906 2,2%

Consolidated revenue for PCAS as of 31 March is down 3% in 2012 compared with 2011.

Pharma Synthesis
Business was affected by the planned reduction in contribution from the new contract between PCAS and Sanofi.  However, it is still more robust than the drop in revenue would suggest, thanks to the manufacture of two products with long production cycles, sales of which will be effective through the second quarter of 2012.

Fine & Speciality Chemicals
Fine & Speciality Chemicals rose slightly by 2.2% in 2012, thanks to the activities of New Technologies whereas, Performance Chemicals and Fragrance-Flavour-Cosmetics are down slightly over the period.

However, these data should not hide the fact that 2012 revenue is still set to be considerably higher than that of 2011.

Confirmation of the Group's development strategy focused on the increase of the percentage of proprietary products and the development of differentiating technologies, coupled with continued rigorous management of all costs, is resulting as from the first quarter of 2012 in significantly higher profitability.

Key operations and events for the quarter

No important events likely to have a significant impact on the company's business or situation occurred during the first quarter of 2012.

Outlook for the current year

As requested by the Board of Directors, the Group's General Management is focusing its action on ensuring sustained improvement in profitability.

Next meeting:
2012 first half sales, on 26 July 2012

 

 

 

 

 

 
 

Founded in 1962, PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 
 
 
PCAS_CAQ1:
http://hugin.info/143512/R/1605084/508120.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1605084
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
09/06 PCAS : Résultats au 1er semestre 2017
09/05 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Août 2017
09/01PCAS SA : half-yearly earnings release
08/22 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Juillet 2017
07/27 PCAS : End of the liquidity contract between PCAS and KEPLER CHEUVREUX
07/19 PCAS : sustained growth in net sales
07/05 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Juin 2017
07/03 PCAS : ex-dividend day for final dividend
06/06 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Mai 2017
05/18 PCAS : Document de référence 2016
More news
Financials (€)
Sales 2017 208 M
EBIT 2017 19,1 M
Net income 2017 10,4 M
Debt 2017 46,1 M
Yield 2017 1,26%
P/E ratio 2017 23,32
P/E ratio 2018 17,49
EV / Sales 2017 1,50x
EV / Sales 2018 1,36x
Capitalization 265 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 17,0 €
Spread / Average Target -3,0%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Scientific Director
Sector and Competitors
1st jan.Capitalization (M$)
PCAS24.75%313
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887